589 related articles for article (PubMed ID: 34463034)
1. Surgical perspective in neoadjuvant chemoimmunotherapy for stage II-III non-small cell lung cancer.
Hong T; Sun T; Zhang M; Liu X; Yuan Y; Dolo PR; Chen B; Zhang H
Thorac Cancer; 2021 Oct; 12(20):2796-2802. PubMed ID: 34463034
[TBL] [Abstract][Full Text] [Related]
2. [Experience of Thoracotomy and Robot-assisted Bronchial Sleeve Resection
after Neoadjuvant Chemoimmunotherapy for Local Advanced Central Lung Cancer].
Liu X; Sun T; Hong T; Yuan Y; Zhang H
Zhongguo Fei Ai Za Zhi; 2022 Feb; 25(2):71-77. PubMed ID: 35224959
[TBL] [Abstract][Full Text] [Related]
3. [Preliminary Efficacy Evaluation of Neoadjuvant Immunotherapy Combined with
Chemotherapy in Resectable Non-small Cell Lung Cancer].
Zhou S; Hao X; Yu D; Liu S; Cao X; Su C; Song X; Xiao N; Li Y; Yang W; Zhao D; Wang J; Liu Z; Xu S
Zhongguo Fei Ai Za Zhi; 2021 Jun; 24(6):420-425. PubMed ID: 34024062
[TBL] [Abstract][Full Text] [Related]
4. Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial.
Sun C; Liu Y; Zhang P; Wang X; Xu Y; Lin X; Ma X; Guo Y; Qiu S; Shao G; Yang Z; Ma K
J Cancer Res Clin Oncol; 2023 Feb; 149(2):819-831. PubMed ID: 35192053
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of surgical resection after neoadjuvant chemoimmunotherapy in locally advanced stage IIIA non-small-cell lung cancer.
Romero Román A; Campo-Cañaveral de la Cruz JL; Macía I; Escobar Campuzano I; Figueroa Almánzar S; Delgado Roel M; Gálvez Muñoz C; García Fontán EM; Muguruza Trueba I; Romero Vielva L; Cano Garcia JR; Martínez Téllez E; Partida González C; Jiménez López MF; Jiménez Maestre U; Mongil Poce R; Sánchez Lorente D; Álvarez Kindelán A; Provencio Pulla M
Eur J Cardiothorac Surg; 2021 Jul; 60(1):81-88. PubMed ID: 33661301
[TBL] [Abstract][Full Text] [Related]
6. A systematic review and meta-analysis of neoadjuvant chemoimmunotherapy in stage III non-small cell lung cancer.
Liu W; Zhang T; Zhang Q; Li L; Xu C
BMC Pulm Med; 2022 Dec; 22(1):490. PubMed ID: 36582007
[TBL] [Abstract][Full Text] [Related]
7. A combined model using pre-treatment CT radiomics and clinicopathological features of non-small cell lung cancer to predict major pathological responses after neoadjuvant chemoimmunotherapy.
Wang F; Yang H; Chen W; Ruan L; Jiang T; Cheng L; Jiang H; Fang M
Curr Probl Cancer; 2024 Jun; 50():101098. PubMed ID: 38704949
[TBL] [Abstract][Full Text] [Related]
8. The surgical perspective in neoadjuvant immunotherapy for resectable non-small cell lung cancer.
Jiang L; Huang J; Jiang S; Rong W; Shen Y; Li C; Tian Y; Ning J; Chen X; Yang Y; Ding Z; Li Z; Luo Q
Cancer Immunol Immunother; 2021 Aug; 70(8):2313-2321. PubMed ID: 33512555
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant sintilimab combined with chemotherapy in resectable locally advanced non-small cell lung cancer: case series and literature review.
Yin C; Hu B; Yang X; Kou L; Tian B; Wang C; Li S; Liu B; Ge J
World J Surg Oncol; 2023 Sep; 21(1):304. PubMed ID: 37749594
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant chemoradiation with paclitaxel/carboplatin for selected Stage III non-small-cell lung cancer: long-term results of a trimodality Phase II protocol.
Hehr T; Friedel G; Steger V; Spengler W; Eschmann SM; Bamberg M; Budach W
Int J Radiat Oncol Biol Phys; 2010 Apr; 76(5):1376-81. PubMed ID: 19864078
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcomes associated with neoadjuvant therapy for the treatment of resectable non-small cell lung cancer in real-world practice.
Huang X; Pang G; Mao Z; Li B; Teng Z; Yang Y; Qiu Z; Chen X; Wang P
Clin Respir J; 2024 May; 18(5):e13761. PubMed ID: 38693705
[TBL] [Abstract][Full Text] [Related]
12. Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non-small cell lung cancer.
Bott MJ; Yang SC; Park BJ; Adusumilli PS; Rusch VW; Isbell JM; Downey RJ; Brahmer JR; Battafarano R; Bush E; Chaft J; Forde PM; Jones DR; Broderick SR
J Thorac Cardiovasc Surg; 2019 Jul; 158(1):269-276. PubMed ID: 30718052
[TBL] [Abstract][Full Text] [Related]
13. [Application of Neoadjuvant Chemoimmunotherapy in Resectable NSCLC].
Wang H; Han Y
Zhongguo Fei Ai Za Zhi; 2023 Nov; 26(11):822-832. PubMed ID: 38061884
[TBL] [Abstract][Full Text] [Related]
14. Radical Minimally Invasive Surgery After Immuno-chemotherapy in Initially-unresectable Stage IIIB Non-small cell Lung Cancer.
Deng H; Liu J; Cai X; Chen J; Rocco G; Petersen RH; Brunelli A; Ng CSH; D'Amico TA; Liang W; He J
Ann Surg; 2022 Mar; 275(3):e600-e602. PubMed ID: 34596079
[TBL] [Abstract][Full Text] [Related]
15. Tumor immune microenvironment predicts the pathologic response of neoadjuvant chemoimmunotherapy in non-small-cell lung cancer.
Han R; Zhang Y; Wang T; Xiao H; Luo Z; Shen C; Li J; Zhao C; Li L; Zhu M; Du H; Tang H; Ma Z; Wang Y; He Y
Cancer Sci; 2023 Jun; 114(6):2569-2583. PubMed ID: 36880750
[TBL] [Abstract][Full Text] [Related]
16. Efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy in potentially resectable stage IIIA/IIIB non-small cell lung cancer: Neo-Pre-IC, a single-arm phase 2 trial.
Sun C; Wang X; Xu Y; Shao G; Chen X; Liu Y; Zhang P; Lin X; Ma X; Qiu S; He H; Yang Z; Ma K
EClinicalMedicine; 2024 Feb; 68():102422. PubMed ID: 38304743
[TBL] [Abstract][Full Text] [Related]
17. Effects of Neoadjuvant Therapy After the Initial Assessment of Operability in Patients with Borderline Operable and Inoperable Stage IIIA Non-small Lung Cancer.
Pilav I; Alihodzic-Pasalic A; Musanovic S; Hadzismailovic A; Pilav A; Kadic K; Custovic O; Dapcevic M
Med Arch; 2020 Oct; 74(5):350-354. PubMed ID: 33424088
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of the PD-1 Inhibitor Combined with Albumin-Bound Paclitaxel and Nedaplatin in Preoperative Neoadjuvant Therapy of Unresectable Stage III Lung Squamous Cell Carcinoma.
Xu H; Wang W; Yin J; Song C; Li L; Sun Z
Drug Des Devel Ther; 2022; 16():4269-4277. PubMed ID: 36540715
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial.
Provencio M; Nadal E; Insa A; García-Campelo MR; Casal-Rubio J; Dómine M; Majem M; Rodríguez-Abreu D; Martínez-Martí A; De Castro Carpeño J; Cobo M; López Vivanco G; Del Barco E; Bernabé Caro R; Viñolas N; Barneto Aranda I; Viteri S; Pereira E; Royuela A; Casarrubios M; Salas Antón C; Parra ER; Wistuba I; Calvo V; Laza-Briviesca R; Romero A; Massuti B; Cruz-Bermúdez A
Lancet Oncol; 2020 Nov; 21(11):1413-1422. PubMed ID: 32979984
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant Immunotherapy Combined with Chemotherapy for Local Advanced Non-Small-Cell Lung Cancer in a Patient with a History of Breast Cancer: A Case Report.
Yang RX; Hei Y; Zhu WT; Wang QR; Zhang HM; Chen Y
Curr Oncol; 2022 Aug; 29(9):6203-6210. PubMed ID: 36135056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
